Sweden has finalised a new framework for reimbursement and pricing applications, moving TLV’s 2026 consultation process into binding implementation from 1 October 2026. The change affects the rules and guidance used when companies seek inclusion of medicines in the national pharmaceutical benefits scheme.
The Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV) announced on 16 June that its new general guidelines for subsidy and pricing will apply from 1 October. New regulations on applications for subsidy and pricing will enter into force on the same date.
The general guidelines are intended to support TLV’s handling and decision-making. They bring together assessment criteria for whether the cost of a medicine is reasonable, including criteria that had previously appeared in individual decisions, economic-evaluation guidance and guidance on price increases.
The application regulations specify the information that companies must submit. TLV says the new regulations build largely on the previous application rules, but add a new title, adjust the definition of a new medicine, introduce a definition of parallel distribution, revise the required content for new-medicine applications and set out the information needed for a simplified procedure for established substances.
The final framework follows two earlier steps covered by LiSAH. In March, TLV proposed moving company-facing application requirements from non-binding material into regulations. In April, it narrowed the proposed high-budget-impact pricing rule, removing the more automatic model for price reductions while retaining high sales value as a possible assessment factor.
When the new framework starts, TLV will revoke the current application rules and general advice on economic evaluations and price increases. The updated company handbook adds practical material on areas including rare conditions, biosimilars, simplified procedures, health-economic templates, tripartite consultations, company questions during applications and EU-level scientific advice.
The final package gives companies a more formal filing standard and a consolidated view of TLV’s decision criteria. It also leaves TLV with case-by-case discretion on budget impact, rather than a fixed price-reduction mechanism linked to sales thresholds.
Source: Dental and Pharmaceutical Benefits Agency, TLV
Link: Nya allmänna riktlinjer och föreskrifter om subvention och prissättning av läkemedel (New general guidelines and regulations on subsidy and pricing of medicines)
Date: 16 June 2026
